Drug Trial Radar · NCT03884881
Second-generation Sequencing Guides the Treatment of Severe Pneumonia
Last checked: Nov 20, 2026Latest source record: Mar 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
400
Actual
Start
Jan 1, 2018
Primary completion
Dec 1, 2019
Study completion Dec 1, 2019
Sponsor
- Lead sponsor
- Xiangya Hospital of Central South UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 21, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigators plan to conduct the participants level, 1:1 randomized trial at the Central ICU and respiratory ICU of Xiangya Hospital in Changsha, China, from January 1, 2018 to December 31, 2019. Participants with initial diagnosis of severe pneumonia will be first treated with empiric therapy, after 48-72 hours, the participants's condition will be evaluated, and participants who will have been initially cured and died should be excluded.The participants who will have failed the initial treatment will be then randomly divided into two groups: the NGS group and the conventional treatment group. Bronchoalveolar lavage fluid will be taken by bedside bronchoscopy when the participants underwent nasal high-flow oxygen therapy, non-invasive ventilation, and invasive ventilation,or venous blood will be taken for examination. Participants in the NGS group will be tested for both NGS and conventional pathogens, however, the routine group will be only routinely tested. According to the pathogen results, participants with non-severe pneumonia will be excluded, and medication should be adjusted under the joint guidance of infectious and respiratory specialists. Then investigators will compare the first outcome: 28-day mortality, and secondary outcome: ICU hospitalization time, mechanical ventilation time, Hospitalization costs, antibiotic use costs, SOFA scores, CURB-65 scores, APACHE scores, and other clinical indicators.
Conditions
- Pneumonia
- Metagenomic Next Generation Sequencing
Interventions
metagenomic next generation sequencingDiagnostic test
Pathogens in the NGS group will be tested by NGS,then according the NGS results, adjust antibiotics
Conventional pathogen detectionDiagnostic test
Morphological detection, microbial culture, nucleic acid amplification technology, serological pathogen antibody titer detection and specific pathogen PCR detection. Then, according to the pathogen results, adjust antibiotics
Meropenem,Imipenem,Caspofene,OsstatDrug
Meropenem,Imipenem,Caspofene,Osstat
Primary outcomes
What the sponsor says the trial is designed to measure.
- mortalityTime frame: 28 day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xiangya Hospital
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.